SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%

Enanta Pharmaceuticals Q2 EPS $(0.300) May Not Compare To $(0.870) Estimate, Sales $27.600M Miss $27.640M Estimate

Enanta Pharmaceuticals (NASDAQ:ENTA) reported quarterly losses of $(0.300) per share which beat the analyst consensus estimate of $(0.870) by 65.52 percent. This is a 250 percent decrease over earnings of $0.200 per

Benzinga · 05/06/2020 20:31

Enanta Pharmaceuticals (NASDAQ:ENTA) reported quarterly losses of $(0.300) per share which beat the analyst consensus estimate of $(0.870) by 65.52 percent. This is a 250 percent decrease over earnings of $0.200 per share from the same period last year. The company reported quarterly sales of $27.600 million which missed the analyst consensus estimate of $27.640 million by 0.14 percent. This is a 30.36 percent decrease over sales of $39.631 million the same period last year.